NCT00171951

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and efficacy of pasireotide in participants with Cushing's disease.

Conditions

• Cushing Disease

Interventions

Type	Name	Description
DRUG	Pasireotide	Pasireotide 600 μg or 900 μg was administered as an SC injection.

Timeline

• Start date: 2004-08-13
• Primary completion: 2013-07-08
• Completion: 2013-07-08
• First posted: 2005-09-15
• Last updated: 2021-06-02
• Results posted: 2021-06-02

Locations

8 sites across 5 countries: United States, France, Germany, Italy, United Kingdom

Regulatory

• FDA-regulated drug study